Company news
Enzolytics Inc. news in 2021
Enzolytics Inc.'s news releases, calls and decks from 2021, newest first.
Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic
December 28, 2021
Enzolytics Announces Progress As It Recognizes World AIDS Day
December 1, 2021
Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072
November 16, 2021
Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology
November 7, 2021
Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
July 28, 2021
Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)
July 25, 2021
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
July 20, 2021
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
July 19, 2021
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe
June 13, 2021
Enzolytics Announces A Comprehensive Therapeutic Protocol For Production Of Monoclonal Antibodies To Address Ongoing And Future Pandemics
June 6, 2021
Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites
May 25, 2021
Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good
May 16, 2021
Enzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US Dollars
May 11, 2021
Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm
May 10, 2021
Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
April 18, 2021
Enzolytics to Present At the Emerging Growth Conference on April 14, 2021
April 11, 2021
CEO Presenting on the Emerging Growth Conference on April 14; Register now
April 12, 2021
Coronavirus Targeted Epitopes Claimed in Enzolytics' Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2)
April 4, 2021
Enzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates
March 21, 2021
Enzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting
March 15, 2021
Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus
March 7, 2021
Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)
February 21, 2021
Enzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments
February 21, 2021
Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases
February 15, 2021
Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus
January 31, 2021
Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application
January 18, 2021
Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit
January 10, 2021